What is the history of Hereditary multiple exostoses?

Hereditary multiple exostoses (HME) was first formally documented in the medical literature during the early 19th century, though skeletal deformities associated with the condition were likely observed throughout human history. Today, we understand Hereditary multiple exostoses as a genetic disorder caused by mutations in the EXT1 or EXT2 genes, representing a significant shift from early historical views that focused solely on the external bony growths.

When was Hereditary multiple exostoses first described?

While ancient skeletal remains show evidence of what we now recognize as Hereditary multiple exostoses, the first clinical descriptions emerged in the 1800s. Sir Astley Cooper, a prominent English surgeon, is often credited with providing early, detailed clinical observations of these bony projections, which he termed "exostoses." Throughout the 19th and early 20th centuries, the condition was frequently referred to as "diaphyseal aclasis," a term reflecting the belief that the disorder was primarily a failure of the bone to remodel correctly during growth.

How has our understanding of Hereditary multiple exostoses evolved?

Historically, medical professionals viewed Hereditary multiple exostoses as a localized structural anomaly. It was not until the late 20th century, with the advent of molecular genetics, that the true nature of the disease was revealed. Researchers discovered that the disorder is inherited in an autosomal dominant pattern. The identification of the EXT1 and EXT2 genes in the 1990s was a watershed moment, proving that the condition is a systemic disorder of heparan sulfate biosynthesis rather than just a simple bone growth issue.

What were the major milestones in the study of this condition?

The history of Hereditary multiple exostoses is marked by several critical scientific breakthroughs that have transformed clinical care:

• 1994: The mapping of the EXT1 gene to chromosome 8q24, providing the first concrete genetic marker for the disease.


• 1995: The discovery of the EXT2 gene on chromosome 11p11, confirming the genetic heterogeneity of the condition.


• Advancements in Imaging: The transition from simple X-rays to advanced MRI and CT scanning allowed surgeons to better map the impact of exostoses on nerves, blood vessels, and tendons.


• Surgical Refinement: The evolution of corrective osteotomies and limb-lengthening procedures has significantly improved the quality of life for those living with Hereditary multiple exostoses.

How have misconceptions about Hereditary multiple exostoses been corrected?

In the past, many practitioners believed Hereditary multiple exostoses could be "cured" simply by removing the bony bumps. We now understand that surgery is indicated primarily for pain, functional impairment, or cosmetic deformity, rather than as a universal fix. Furthermore, the historical fear that all exostoses would inevitably turn malignant has been tempered by modern data, which suggests that while the risk of chondrosarcoma (a type of bone cancer) exists—estimated at approximately 1% to 5% over a lifetime—it is not an inevitable outcome for every patient.

The role of the community in modern research

The patient experience has shifted from isolation to active participation in research. Today, platforms like DiseaseMaps.org connect 266 members, allowing for a collective understanding of the daily challenges of Hereditary multiple exostoses. This community-driven data helps researchers understand the variability of the condition, which can range from mild skeletal changes to severe growth disturbances, influencing how we approach personalized treatment plans today.

Next steps

• Consult with an orthopedic oncologist or a geneticist to discuss the specific genetic mutations involved in your diagnosis.


• Maintain a consistent schedule of imaging to monitor any changes in existing exostoses.


• Join the DiseaseMaps.org community to share experiences and learn from the 266 other members managing this condition.


• Stay informed about current clinical research via the NIH GARD database.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hereditary Multiple Exostoses.


• Orphanet: Multiple Osteochondromas (Hereditary Multiple Exostoses).


• Online Mendelian Inheritance in Man (OMIM): Entry #133700 (EXT1) and #608177 (EXT2).